DISCLOSURE
Cancer
DER, FOUNDERS, CANCER
This project was funded by VUB-IOF INTEGRAL, Stichting tegen Kanker, and Research Foundation–Flanders. Catarina Xavier, Laurens Raes, Johannes Heemskerk, Hendrik Everaert, Christel Fontaine, Denis Schallier, Ilse Vaneycken, and Vicky Caveliers have nothing to disclose. Odrade Gondry and Quentin Lecocq received an Emmanuel Van der Schueren Grant funded by Kom op tegen Kanker (Stand up to Cancer), the Flemish Cancer Society. Geert Raes, Nick Devoogdt, and Tony Lahoutte are consultants for Precirix. Geert Raes, Nick Devoogdt, Tony Lahoutte, Jo Van Ginderachter, and Marleen Keyaerts are founders and shareholders in Abscint NV/SA. Geert Raes, Nick Devoogdt, Tony Lahoutte, Jo Van Ginderachter, Marleen Keyaerts, Karine Breckpot, and Quentin Lecocq hold patents related to sdAb imaging and therapy. Jo Van Ginderachter, Geert Raes, Nick Devoogdt, Odrade Gondry, Tony Lahoutte, and Marleen Keyaerts are supported by the EU/EFPIA/Innovative Medicines Initiative 2 Joint Undertaking Immune-Image grant 831514. ND reports grants, personal fees, and nonfinancial support from Precirix and nonfinancial support from Abscint. Lore Decoster received fees for advisory boards, speakers, research, and travel grants to Universitair Ziekenhuis Brussel from BMS, MSD, Roche, Bhoeringer Ingelheim, Astra Zeneca, Lilly, and Servier. Sandrine Aspeslagh declares memberships on an advisory board or board of directors for MSD, Sanofi, Roche, BMS, Pfizer, and Galapagos. Tony Lahoutte and Marleen Keyaerts have an FWO clinical mandate. No other potential conflict of interest relevant to this article was reported.